METiS TechBio Debuts on Hong Kong Exchange as World's First Publicly Listed AI-Powered Drug Delivery Company
核心洞察
METiS TechBio (搜索) successfully listed on the Hong Kong Stock Exchange (搜索), becoming the world's first publicly listed AI-powered drug delivery company and raising over HKD 2.1 billion in proceeds.
The company's shares surged 173% on debut, with the IPO oversubscribed by more than 6,900 times and attracting 18 cornerstone investors including BlackRock (搜索) with USD 50 million.
METiS TechBio (搜索)'s proprietary NanoForge (搜索) AI platform has developed MTS-004, China's first AI-enabled formulation drug to complete Phase III trials for pseudobulbar affect (搜索) treatment.
METiS TechBio (搜索) made a spectacular debut on the Hong Kong Stock Exchange (搜索), with shares surging 173% as the AI-driven drug delivery company became the world's first publicly listed firm in this sector. The company raised over HKD 2.1 billion (USD 269.5 million) from the sale of 201.23 million shares at HKD 10.50 each, marking the largest healthcare IPO fundraising in Hong Kong for 2026.
The IPO drew extraordinary investor demand, with the Hong Kong public offering oversubscribed by more than 6,900 times, locking up over HKD 730 billion in subscription funds. International institutional investors showed equally strong interest, with more than 280 institutional investors participating and recording 82 times oversubscription for the allocable tranche.
Revolutionary AI-Powered Nanodelivery Platform
Co-founder and CEO Dr. Chris Lai, who holds a PhD from MIT, positioned the company as the "SpaceX of pharmaceuticals." He explained that artificial intelligence has shortened drug development timelines from years to just 18 months. "We use AI algorithms to design a large number of nano-rockets. Pharma companies can load their own drugs onto our rockets through nanodelivery platforms to make products," Lai stated.
The company's core innovation lies in its proprietary NanoForge (搜索) AI nanodelivery platform, which encompasses AI foundation models, METiS AI agents, quantum chemistry and molecular dynamics simulations, and an AI-driven high-throughput screening platform. METiS TechBio (搜索) has built the world's largest ionizable lipid library at the scale of tens of millions and independently developed the world's only algorithm for de novo lipid generation and lipid language model.
Breakthrough Clinical Achievements
METiS TechBio (搜索) has achieved significant clinical milestones with MTS-004, China's first AI-enabled formulation drug to complete a Phase III clinical trial. MTS-004 represents the first and only pseudobulbar affect (搜索) (PBA) drug in China to have completed clinical trials and is expected to fill the treatment gap for PBA in the Chinese market.
The development timeline for MTS-004 demonstrates the power of AI acceleration, taking only 38 months from project initiation to completion of Phase III trials. Through the company's AiTEM predictive analytics and advanced modeling technologies, preclinical formulation development time was reduced from one to two years to less than three months.
Comprehensive Pipeline and Targeted Delivery Capabilities
Based on the NanoForge (搜索) platform, METiS TechBio (搜索) has achieved precision targeted delivery to eight key organs and tissues: the liver, lungs, heart, muscles, tumor tissues, immune system, central nervous system, and gastrointestinal tract. The company's pipeline includes more than 10 products covering oncology, immunology, central nervous system disorders, and metabolic diseases.
A standout candidate is MTS-105, designed as a potential world-first in vivo mRNA-encoded T-cell engager (TCE) therapy for solid tumors (搜索), specifically targeting liver cancer (搜索) and other advanced solid tumors with liver metastases. MTS-105 is currently in the investigator-initiated trial stage and has received Orphan Drug Designation from the U.S. FDA.
Strong Financial Backing and Commercial Validation
The IPO featured an unprecedented lineup of 18 cornerstone investors subscribing for USD 148 million, led by BlackRock (搜索)'s USD 50 million investment. The investor base included global asset management giants UBS Asset Management Singapore, Mirae Asset of South Korea, and ORIX Corporation of Japan, alongside specialized healthcare funds including Deerfield, RTW, and Lake Bleu Capital.
METiS TechBio (搜索) recorded revenue of RMB 105 million in 2025, primarily from upfront payments for the MTS-004 product partnership. The total milestones for MTS-004 in the PBA indication amount to RMB 1.845 billion, with additional potential milestone payments of up to RMB 100 million for indication expansion.
Strategic Investment in R&D and Talent
The company maintains a robust R&D infrastructure with centers in Beijing and Hangzhou, employing more than 100 scientists and technical personnel, including approximately 40 PhD holders. From 2023 to 2025, METiS TechBio (搜索) sustained high R&D expenditure of approximately RMB 270 million, with the majority of operating expenses dedicated to research and development.
Looking forward, approximately 50% of IPO proceeds will support core technology research and AI infrastructure advancement, 20% will fund ongoing and planned clinical trials across multiple therapeutic areas, and 10% will develop animal health and anti-aging solutions. As of the latest practicable date, the company had filed 224 patent applications and been granted 52 patents, establishing a strong intellectual property foundation for its innovative platform.